CLINICAL EFFICACY OF REMICADE IN CBD

CBD REMICADE 的临床疗效

• 批准号: 7719391
• 负责人: LISA A MAIER
• 金额: $ 0.06万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719391
• 关键词: Adverse effects; Alloys; Beryllium; Breathing; Chest; Chronic berylliosis; Clinical; Clinical effectiveness; Computer Retrieval of Information on Scientific Projects Database; Condition; Diagnosis; Disease; Disease Progression; Exercise stress test; Funding; Grant; Immune System Diseases; Inflammation; Institution; Lung; Lung Inflammation; Other Therapy; Oxygen; Patients; Pharmaceutical Preparations; Prednisone; Pulmonary function tests; Recurrent disease; Research; Research Personnel; Resources; Restart; Source; Staging; Steroids; Symptoms; Testing; Tumor Necrosis Factor-alpha; United States National Institutes of Health; Workplace; clinical efficacy; design; follow-up; human TNF protein; improved; infliximab; particle; research clinical testing; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic Beryllium Disease (CBD) is an immune system disorder caused by the inhalation of beryllium particles. Exposures and disease occurs in workplaces in which beryllium and beryllium alloys are used, producing disease in 2-6% of workers. Prednisone is the most commonly prescribed treatment for CBD. Cessation of the drug usually leads to relapse of the disease symptoms. Restarting steroid treatment usually improves the patient's condition, however, continual use of prednisone can cause a variety of side effects. Even with steroid treatment, many patients still continue to worsen. The treatment may slow the clinical progression of disease, but often does not halt that progression. In some patients CBD does not respond to prednisone or other therapy and can be fatal if diagnosed at intermediate or late stages. As such, there is a need to test promising new therapies for this disorder. This research study is designed to test the clinical effectiveness of a drug called infliximab in CBD. This drug may reduce a substance called TNF-alpha, which is associated with more severe disease and inflammation in the lung. Receiving infliximab may help with symptoms and may improve clinical testing, such as breathing tests. Baseline and follow up testing will look for improvements in breathing tests (Pulmonary Function Testing), exchange of oxygen in the lungs (exercise test), chest x-ray, and lung inflammation.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 慢性铍疾病（CBD）是由铍颗粒吸入引起的免疫系统疾病。 暴露和疾病发生在使用铍和铍合金的工作场所中，在2-6％的工人中产生疾病。 泼尼松是CBD最常见的治疗方法。 停止药物通常会导致疾病症状复发。 重新启动类固醇治疗通常会改善患者的病情，但是，泼尼松的持续使用会导致多种副作用。 即使接受类固醇治疗，许多患者仍然继续恶化。 治疗可能会减慢疾病的临床进展，但通常不会停止这种进展。 在某些患者中，CBD对泼尼松或其他疗法无反应，如果在中间或晚期被诊断出可能是致命的。 因此，有必要测试该疾病的有希望的新疗法。 这项研究旨在测试CBD中称为英夫利昔单抗药物的临床有效性。 该药物可以减少一种称为TNF-α的物质，该物质与肺部更为严重的疾病和炎症有关。 接受英夫利昔单抗可能有助于症状，并可能改善临床测试，例如呼吸测试。 基线和后续测试将寻找呼吸测试（肺功能测试），肺中氧气的交换（运动测试），胸部X射线和肺部炎症的改善。